Joel Lewis - 16 Jan 2026 Form 4 Insider Report for GALECTIN THERAPEUTICS INC (GALT)

Role
President and CEO, Director
Signature
Jack W. Callicutt
Issuer symbol
GALT
Transactions as of
16 Jan 2026
Net transactions value
$0
Form type
4
Filing time
21 Jan 2026, 16:48:29 UTC
Previous filing
13 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
LEWIS JOEL President and CEO, Director C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS Jack W. Callicutt 21 Jan 2026 0001725595
This filing has been restated, see here for the amended filing

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GALT Stock option (right to buy) Award $0 +84,000 $0.000000 65,000 16 Jan 2026 Common Stock 84,000 $3.04 Direct F1, F2
transaction GALT Restricted Stock Unit Award $0 +120,000 $0.000000 100,000 16 Jan 2026 Common Stock 120,000 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2 The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.
F3 Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.
F4 The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.